Analysts Have Conflicting Sentiments on These Healthcare Companies: Cormedix (CRMD), Immatics (IMTX) and Johnson & Johnson (JNJ)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cormedix (CRMD – Research Report), Immatics (IMTX – Research Report) and Johnson & Johnson (JNJ – Research Report).

Cormedix (CRMD)

In a report released yesterday, Jason Butler from JMP Securities reiterated a Buy rating on Cormedix, with a price target of $19.00. The company’s shares closed last Tuesday at $3.13, close to its 52-week low of $2.94.

According to TipRanks.com, Butler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.0% and a 32.3% success rate. Butler covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Vigil Neuroscience Inc, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cormedix with a $12.50 average price target.

See the top stocks recommended by analysts >>

Immatics (IMTX)

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Immatics yesterday and set a price target of $25.00. The company’s shares closed last Tuesday at $9.70.

According to TipRanks.com, Livshits is a 5-star analyst with an average return of 25.6% and a 38.8% success rate. Livshits covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Iovance Biotherapeutics, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immatics with a $18.80 average price target, representing a 95.8% upside. In a report issued on November 2, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock.

Johnson & Johnson (JNJ)

Stifel Nicolaus analyst Rick Wise maintained a Hold rating on Johnson & Johnson yesterday and set a price target of $155.00. The company’s shares closed last Tuesday at $147.66, close to its 52-week low of $144.95.

According to TipRanks.com, Wise is a 4-star analyst with an average return of 4.1% and a 55.8% success rate. Wise covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Zimmer Biomet Holdings, and Edwards Lifesciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Johnson & Johnson with a $176.95 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CRMD:

• CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update
• CorMedix options imply 36.0% move in share price post-earnings
• CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
• CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
• CorMedix announces abstract presentation at IDWeek conference